XML 24 R19.htm IDEA: XBRL DOCUMENT
v3.19.3

Fair value measurement | 9 Months Ended
--- | ---
Sep. 29, 2019
Fair Value Disclosures [Abstract] |
Fair value measurement | Fair value measurement For a description of the fair value hierarchy, see Note 11 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of September 29, 2019 and December 31, 2018:
| Total carrying value at September 29, 2019 |  | Quoted prices in active markets (Level 1) |  | Significant other observable Inputs (Level 2) |  | Significant unobservable Inputs (Level 3)
| (Dollars in thousands) |  |  |  |  |  |
Investments in marketable securities | $ | 10,168 |  |  | $ | 10,168 |  |  | $ | — |  |  | $ | — |
Derivative assets | 51,898 |  |  | — |  |  | 51,898 |  |  | — |
Derivative liabilities | 932 |  |  | — |  |  | 932 |  |  | — |
Contingent consideration liabilities | 206,880 |  |  | — |  |  | — |  |  | 206,880 |
| Total carrying value at December 31, 2018 |  | Quoted prices in active markets (Level 1) |  | Significant other observable Inputs (Level 2) |  | Significant unobservable Inputs (Level 3)
| (Dollars in thousands) |  |  |  |  |  |
Investments in marketable securities | $ | 8,671 |  |  | $ | 8,671 |  |  | $ | — |  |  | $ | — |
Derivative assets | 16,050 |  |  | — |  |  | 16,050 |  |  | — |
Derivative liabilities | 8,581 |  |  | — |  |  | 8,581 |  |  | — |
Contingent consideration liabilities | 304,248 |  |  | — |  |  | — |  |  | 304,248 |
There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the nine months ended September 29, 2019. Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. The Company uses foreign currency forward contracts and cross-currency interest rate swap agreements to manage foreign currency transaction exposure, exposure to foreign currency denominated monetary assets and liabilities and exposure to the effect of variability in the U.S. dollar to euro exchange rate. The Company measures the fair value of the foreign currency forward and cross-currency swap agreements by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs (inputs that are not observable in the market) are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions, which are discussed immediately below. Contingent consideration Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates. The Company determines the fair value of the contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn out-period using management's best estimates) or a probability-weighted discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration.
Contingent Consideration Liability |  | Valuation Technique |  | Unobservable Input |  | Range
Milestone-based payments |  |  |  |  |  |
|  | Discounted cash flow |  | Discount rate |  | 3.1% - 3.7%
|  |  |  | Projected year of payment |  | 2020 - 2023
Revenue-based payments |  |  |  |  |  |
|  | Monte Carlo simulation |  | Revenue volatility |  | 18.6% - 23.9%
|  |  |  | Risk free rate |  | Cost of debt structure
|  |  |  | Projected year of payment |  | 2020 - 2022
|  | Discounted cash flow |  | Discount rate |  | 10.0%
|  |  |  | Projected year of payment |  | 2019 - 2029
The following table provides information regarding changes in the Company's contingent consideration liabilities during the nine months ended September 29, 2019:
| Contingent consideration
| 2019
| (Dollars in thousands)
Balance - December 31, 2018 | $ | 304,248 |
Payments (1) | (138,098) |
Revaluations | 40,894 |
Translation adjustment | (164) |
Balance - September 29, 2019 | $ | 206,880 |
(1) Consists mainly of a $106.8 million payment associated with the Company's acquisition of NeoTract, Inc. and resulting from the achievement of a revenue-based goal for the period from January 1, 2018 to December 31, 2018 and $30.0 million of payments associated with the Company's acquisition of Essential Medical, Inc. and resulting from achievement of a regulatory goal.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration